Q2 EPS Estimates for Exact Sciences Boosted by William Blair

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Analysts at William Blair boosted their Q2 2025 EPS estimates for shares of Exact Sciences in a research report issued to clients and investors on Monday, June 30th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings of $0.06 per share for the quarter, up from their previous forecast of ($0.07). The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences' Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.22 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.35 EPS and FY2026 earnings at $1.02 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 36.06% and a negative return on equity of 3.75%. The business had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. During the same period in the previous year, the firm earned ($0.60) EPS. The business's revenue for the quarter was up 10.9% compared to the same quarter last year.

Several other brokerages also recently weighed in on EXAS. Royal Bank Of Canada boosted their target price on shares of Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Robert W. Baird upped their price objective on shares of Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Guggenheim reissued a "buy" rating and set a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th. Mizuho began coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 target price for the company. Finally, Barclays decreased their price target on Exact Sciences from $75.00 to $65.00 and set an "overweight" rating for the company in a report on Tuesday, June 24th. Two investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Exact Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $70.40.

Exact Sciences Price Performance

Shares of Exact Sciences stock traded down $1.05 on Wednesday, hitting $52.82. The company's stock had a trading volume of 1,668,708 shares, compared to its average volume of 2,583,850. Exact Sciences has a 52-week low of $39.97 and a 52-week high of $72.83. The company has a quick ratio of 2.38, a current ratio of 2.73 and a debt-to-equity ratio of 0.97. The firm has a fifty day moving average price of $53.73 and a 200-day moving average price of $51.19. The company has a market capitalization of $9.96 billion, a P/E ratio of -9.59, a price-to-earnings-growth ratio of 11.39 and a beta of 0.95.

Institutional Investors Weigh In On Exact Sciences

A number of hedge funds have recently added to or reduced their stakes in EXAS. Larson Financial Group LLC raised its stake in shares of Exact Sciences by 2,804.8% during the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company's stock valued at $26,000 after purchasing an additional 589 shares in the last quarter. National Pension Service raised its position in Exact Sciences by 75.1% in the first quarter. National Pension Service now owns 681 shares of the medical research company's stock worth $29,000 after acquiring an additional 292 shares in the last quarter. SVB Wealth LLC purchased a new position in Exact Sciences in the 1st quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Exact Sciences in the 1st quarter worth about $34,000. Finally, Banque Cantonale Vaudoise purchased a new position in Exact Sciences in the 1st quarter worth about $34,000. 88.82% of the stock is currently owned by institutional investors.

Insider Transactions at Exact Sciences

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $53.20, for a total value of $170,612.40. Following the sale, the director directly owned 72,759 shares in the company, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.